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study question: Do women with BRCA1 or BRCA2 mutations have reduced ovarian reserve, as measured by circulating anti-Mu¨llerian
hormone (AMH) concentration?
summaryanswer: Women with a germline mutation in BRCA1 have reduced ovarian reserve as measured by AMH.
what is known already: The DNA repair enzymes encoded by BRCA1 and BRCA2 are implicated in reproductive aging. Circulating
AMH is a biomarker of ovarian reserve and hence reproductive lifespan.
study design, size, duration: Thiswas a cross-sectional study of AMHconcentrations of 693women at the time of enrolment into
theKathleenCuninghamFoundationConsortium for research in the Familial BreastCancer (kConFab) cohort study (recruitment from19August
1997 until 18 September 2012). AMH was measured on stored plasma samples between November 2014 and January 2015 using an electro-
chemiluminescence immunoassay platform.
participants/materials, setting, methods: Eligiblewomenwere from families segregatingBRCA1 or BRCA2mutations and
had knownmutation status. Participants were aged 25–45 years, had no personal history of cancer, retained both ovaries andwere not pregnant
or breastfeeding at the time of plasma storage. CirculatingAMHwasmeasured for 172 carriers and 216 non-carriers from families carryingBRCA1
mutations, and 147 carriers and 158 non-carriers from families carrying BRCA2mutations. Associations between plasmaAMHconcentration and
carrier statuswere tested by linear regression, adjusted for age at plasma storage, oral contraceptive use, bodymass index and cigarette smoking.
main results and the role of chance: Mean AMH concentration was negatively associated with age (P, 0.001). Mutation
carriers were younger at blood draw than non-carriers (P ≤ 0.031). BRCA1 mutation carriers had, on average, 25% (95% CI: 5%–41%,
P ¼ 0.02) lower AMH concentrations than non-carriers and were more likely to have AMH concentrations in the lowest quartile for age (OR
1.84, 95%CI: 1.11–303, P ¼ 0.02). Therewasnoevidenceof an associationbetweenAMHconcentration andBRCA2mutation status (P ¼ 0.94).
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limitations, reasons for caution: AMH does not directly measure the primordial follicle pool. The clinical implications of the
lower AMH concentrations seen in BRCA1 mutation carriers cannot be assessed by this study design.
wider implications of thefindings:Womenwith a germlinemutation in BRCA1mayhave reduced ovarian reserve. This is con-
sistent with other smaller studies in the literature and has potential implications for fertility and reproductive lifespan.
study funding/competing interest(s): kConFab is supported by a grant from the Australian National Breast Cancer Foun-
dation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of
New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. K.A.P. is an Australian National
Breast Cancer Foundation Practitioner Fellow. J.L.H. is a NHMRC Senior Principal Research Fellow. M.H. is a NHMRC Practitioner Fellow.
R.A.A. reports personal fees from RocheDiagnostics & BeckmanCoulter outside the submitted work and C.S. reports other earnings fromMel-
bourne IVF outside the submitted work. The remaining authors have nothing to declare and no conﬂicts of interest.
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Introduction
Germline mutations in the BRCA1 or BRCA2 genes substantially increase
the risk of breast cancer, high grade serous ovarian cancer, fallopian tube
cancer and primary peritoneal cancer (Antoniou et al., 2003). Less is
known about the non-cancer-related implications, but preliminary data
suggest that ovarian reserve, and hence fertility, may be reduced in
BRCA1 mutation carriers (Oktay et al., 2010, 2014; Titus et al., 2013;
Pavone et al., 2014;Wang et al., 2014). If conﬁrmed, this could have clin-
ical consequences for pregnancy planning, reproductive lifespan and
perhaps ovarian function following chemotherapy.
BRCA1 and BRCA2 are integral in the repair of DNA double-strand
breaks through homologous recombination, and thus are important
members of the ATM-mediated DNA damage signalling pathway
(Jackson and Bartek, 2009). The importance of inefﬁcient DNA double-
strand break repair in carcinogenesis is well understood (Jackson and
Bartek, 2009) but recently, inefﬁcient DNA repair has also been
shown to contribute to oocyte aging. The protective function of double-
strandDNA repair proteins, including BRCA1, declines with age, leading
to accumulation of lethal DNA double-strand breaks and oocyte apop-
tosis (Titus et al., 2013). Data frommousemodels suggest that inheriting
a BRCA1 germline mutation may accelerate this process: BRCA1 hetero-
zygous mutant mice have smaller litter sizes, produce fewer oocytes in
response to ovarian stimulation and their oocytes accumulate DNA
damage more quickly than wild-type mice or mice with germline
BRCA2 mutations (Titus et al., 2013).
Circulating anti-Mu¨llerian hormone (AMH) is the best currently avail-
able biomarker to forecast age at menopause and thus the reproductive
lifespan (Sowers et al., 2008; Broer et al., 2011; Tehrani et al., 2013). It is
widely used to predict ovarian response in assisted reproductive tech-
nologies (Iliodromiti et al., 2014), although its relationship to natural fer-
tility is less clear (Steiner et al., 2011; Hagen et al., 2012). AMH
production begins prenatally, peaks in the mid-20s and then declines
to the menopause (Kelsey et al., 2011). AMH is produced by the granu-
losa cells of growing pre-antral and early antral follicles, but not by the
primordial follicles which are the true arbiter of female reproductive life-
span. Thus AMH directly assesses ovulatory potential within about a
6-month timeframe (Findlay et al., 2015). Nevertheless AMH approxi-
mates primordial follicle number and can be used to assess ovarian
reserve in women aged 25 years and over (Broer et al., 2011; Hansen
et al., 2011). Circulating levels remain relatively constant across themen-
strual cycle (Tsepelidis et al., 2007) and also between cycles in the same
woman (Fanchin et al., 2005). Current oral contraceptive pill (OCP) use
and cigarette smoking are associated with lower AMH concentrations
(Dolleman et al., 2013), whereas markedly elevated levels are found in
polycystic ovary syndrome (PCOS) (Iliodromiti et al., 2013).
This study was conducted to determine whether women with a muta-
tion inBRCA1orBRCA2have reducedovarian reserve, asmeasured by cir-
culating AMHconcentrations, comparedwithwomenwho do not carry a
BRCA1orBRCA2mutation. It was hypothesized that AMHconcentrations
would be lower in mutation carriers compared with non-carriers, that
AMHwould be lower in BRCA1mutation carriers than in BRCA2mutation
carriers, and that thedifferencebetweenAMHconcentrationsofmutation
carriers and non-carriers would be greater at older ages.
Methods
Subjects
Eligible women were from Australian and New Zealand families, with mul-
tiple cases of breast cancer, who were enrolled in the Kathleen Cuningham
Foundation Consortium for Research into Familial Breast Cancer
(kConFab) Cohort Study (Mann et al., 2006). Recruitment to that cohort,
which currently includes 1636 families, commenced on 19 August 1997
and is ongoing. Individuals had been recruited to kConFab after at least
one family member attended a clinical consultation in any of 24 Family
Cancer Centres. At the time of cohort entry, participants provided blood
for both genetic testing and storage of plasma. Participants in the cohort
have been followed up every three years (Phillips et al., 2005). All participants
provided written informed consent, and the kConFab Cohort Study has In-
stitutional Review Board approval at recruiting sites.
Women eligible for the study reported here either had a pathogenic mu-
tation, splice site mutation or large deletion in BRCA1 or BRCA2 (‘mutation
carriers’), or were a blood relative of a mutation carrier and had themselves
been tested and found not to carry the identiﬁed family-speciﬁc mutation
(‘non-carriers’). At the time of blood draw, they had to be aged 25–45
years, have two intact ovaries, no personal history of any cancer (apart
from non-melanoma skin cancer), no history of primary amenorrhoea and
not pregnant or breastfeeding. The Institutional Review Board of the Peter
MacCallum Cancer Centre approved this study.
Data collection
At cohort entry, kConFab Cohort Study participants completed an epide-
miologic questionnaire (John et al., 2004). Data collected include demo-
graphics, height and weight, personal and family cancer history,
oophorectomy status, menstrual history, parity, breastfeeding history,
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OCP use and fertility treatment and cigarette smoking. Additional datawere
collected on the day of blood draw, including current pregnancy status, date
of commencement of last menstrual cycle, self-reported menopausal status
and current OCP use.
AMH analysis
A blood sample was collected at enrolment into the kConFab Cohort Study.
Plasma aliquots were stored at 2808C within 48 h. AMH measurements,
blinded toparticipantmutation status,wereundertakenbetweenNovember
2014and January 2015, at theMelbourne IVFEndocrine Laboratoryutilizing a
fully automated Elecsysw AMH assay on the Cobas e electrochemilumines-
cence immunoassay platform (Gassner and Jung, 2014; Anderson et al.,
2015). The lowest level of detection was 0.07 pmol/l and the intra-assay
and inter-assay imprecision coefﬁcients of variation at 7.0 pmol/l were
4.6 and 5.6% respectively. Plasma samples had been stored for a mean
of 11.4 years (standard deviation [SD]: 3.6) prior to AMH analysis and
none had been previously thawed. Quality assurance testing was per-
formed on 30 non-study samples for which both plasma and serum were
available; AMH concentrations using serum samples were approximately
5% higher than those using plasma. It was considered that this would not
affect the study conclusions given that plasma was used for both the com-
parison groups.
Statistical methods
Comparisonsof participant characteristics by carrier statusweremadebyap-
plying Fisher’s exact test forcategorical variables andWilcoxon rank-sumtest
for numerical variables. For each gene (BRCA1 and BRCA2), a difference in
mean AMH concentration between mutation carriers and non-carriers
was tested by linear regression, modelling the natural logarithm of AMH as
the outcome variable and carrier status as the explanatory variable. This
log transformation was applied to correct for the asymmetry in the distribu-
tion of AMH values, as consistently reported in other studies (Su et al., 2013;
Whitworth et al., 2015). The exponential of the regression coefﬁcient for
carrier status (and its 95% conﬁdence interval (CI) limits) was taken as an es-
timate of mean AMH concentration on the natural scale for carriers relative
to non-carriers. For three samples, the AMH concentration was below the
lower limit of detection of 0.07 pmol/l and these were set to a value of
0.07 pmol/l for the purposes of the analysis. Multivariable models incorpo-
rated factors known to affect ovarian reserve, including age at blood draw
(by including a linear and quadratic term for the age range considered, as sug-
gested by Kelsey et al (Kelsey et al., 2011)), body mass index (BMI) at cohort
entry, cigarette smoking at cohort entry (never/past/current regular cigarette
use), and OCP use at time of blood draw (no/yes). Robust standard errors
were estimated to account for the inclusion of multiple women from the
same families. Sensitivity analyses were conducted, excluding women who
were using the OCP at the time of blood draw and, separately, excluding
women who reported being post-menopausal or had unknown menopausal
status at blood draw. To assesswhether any difference inmeanAMH concen-
trationbetweencarriers andnon-carrierswasmorepronouncedatolder ages,
we ﬁt an additional parameter for the interaction between mutation carrier
status and the linear term for age. We also estimated the odds ratio (OR)
for having anAMH level in the lowest quartile for age in years, by logistic regres-
sion,with the samecovariates as in the primary analysis. All P-valueswere two-
sided and those less than0.05were considered statistically signiﬁcant. Statistic-
al analyses were performed by R.L.M.
Results
Participants
At the time of AMHanalysis, therewere 1021women aged 25–45 years
enrolled in the kConFab Cohort Study who were blood relatives in a
family with a mutation in either BRCA1 or BRCA2. Of these, 328 were
excluded due to: unilateral or bilateral oophorectomy prior to blood
draw (134), a personal historyof cancer prior to blood draw (166), preg-
nancy or breastfeeding at the time of blood draw (14), pathogenic muta-
tions in both the BRCA1 and BRCA2 genes (4), or inadequate sample for
AMH testing (10). Thus 693 participants were included in the ﬁnal study
sample, including 172 carriers of a pathogenic mutation in BRCA1, 216
women who tested negative for the known BRCA1 mutation in their
family, 147 carriers of a pathogenic mutation in BRCA2 and 158
women who tested negative for the known BRCA2 mutation in their
family.
Participant characteristics are shown inTable I. Themean age at blood
draw was 35.1 years and mutation carriers were younger than non-
carriers (P ≤ 0.03). Of the subjects, 24% reported current cigarette
use at cohort entry and this did not differ between mutation carriers
and non-carriers (P ≥ 0.31). BRCA1 mutation carriers had lower BMI
than non-carriers (P ¼ 0.02), but there was no signiﬁcant difference in
BMI between BRCA2 mutation carriers and non-carriers (P ¼ 0.99).
There were no signiﬁcant differences between carriers of BRCA1 and
BRCA2 mutations and non-carriers for OCP use at the time of blood
draw (P ≥ 0.08) or for surrogatemeasures of ovarian function, including
parity (P ≥ 0.33), age at ﬁrst birth (P ≥ 0.76) and history of infertility
treatments (P ≥ 0.64).
AMH concentrations were negatively associated with age overall
and for both carriers and non-carriers of BRCA1 and BRCA2 mutations
(P, 0.001). AMH concentrations were, on average, 28% lower
(exp(b) ¼ 0.72, 95% CI ¼ 0.58–0.89; P ¼ 0.003) for current OCP
users compared with non-users. AMH concentrations were not asso-
ciated with the length of time between blood draw and AMH analysis
(P ¼ 0.08), smoking status (P ¼ 0.55) or BMI (P ¼ 0.92).
After adjusting for age at blood draw, BRCA1 carrier status was
associatedwithAMHconcentration (Fig. 1); on average BRCA1mutation
carriers had 25% lower AMH concentrations than non-carriers
(exp(b) ¼ 0.75, 95% CI ¼ 0.59–0.95; P ¼ 0.02). There was no evi-
dence that this association varied with age (P-interaction ¼ 0.61). As
shown in Table II, further adjustment for OCP use at time of blood
draw, BMI at cohort entry and cigarette smoking ever, had little effect
on these estimates (exp(b) ¼ 0.75, 95% CI ¼ 0.58–0.97), nor did ad-
justment for length of time from blood draw to analysis (exp(b) ¼
0.76, 95% CI ¼ 0.59–0.97) or exclusion of current OCP users and
women who reported they were post-menopausal (exp(b) ¼ 0.74,
95% CI ¼ 0.58–0.94). Based on the quadratic model ﬁt for age using
our data for non-carriers, the difference in average AMH concentration
was approximately equivalent to that between a 37 year-old compared
with a 35 year-old woman.
There was no difference in average AMH concentrations between
BRCA2 mutation carriers and non-carriers (exp(b) ¼ 0.99, 95% CI ¼
0.77–1.27; P ¼ 0.94), after adjusting for age (Fig. 2), and for OCP use,
BMI and cigarette smoking. Results were consistent after further adjust-
ment for time from blood draw to analysis and the exclusion of current
OCP users and post-menopausal women (P ≥ 0.85).
The estimated OR for having an AMH concentration in the lowest
quartile for age was 1.84 (95% CI 1.11–3.03, P ¼ 0.02) for BRCA1 mu-
tation carriers and 0.87 (95% CI 0.51–1.47, P ¼ 0.59) for BRCA2muta-
tion carriers.
Information was not available regarding whether women had PCOS,
which is known to result in highAMHconcentrations, howeverexcluding
BRCA1 or BRCA2 mutations and serum AMH levels 3
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women with AMH concentrations in the highest quartile from the ana-
lysis did not substantially change the estimates obtained.
Discussion
BRCA1 and BRCA2 mutation carriers are rare in the general population
(about 0.1 and 0.2% respectively) (Antoniou et al., 2008), although they
are much more prevalent in some subgroups due to founder effects, for
example 1.2 and 1.5% respectively in Ashkenazi Jews (Roa et al., 1996).
Whilst the increased cancer risk implications of having these germline
mutations are well-described, much less is known about the non-cancer
implications. This is the ﬁrst large study to ﬁnd that BRCA1 germlinemuta-
tions are associated with lower than expected AMH, an established bio-
marker of ovarian reserve. Low AMH concentrations have not been
shown to affect natural fecundability in young women (Hagen et al.,
2012) but are associated with reduced fecundability in older women in
their 30s (Steiner et al., 2011). The reduced concentrations of AMH
observed in this study were equivalent, for example, to a two year age in-
crease for a woman in her mid 30s. Thus it is possible that the ﬁndings of
our study might not translate to clinically relevant fertility implications for
younger women, but may be important for the subgroup of BRCA1muta-
tion carriers who wish to conceive in their late 30s or 40s when fertility is
reduced even in the general population.
Figure 1 AMH levels in BRCA1mutation carrier families, bymutation
carrier status. Solid and dashed lines are drawn by locally weighted re-
gression of log-transformed AMH levels. Carriers: crosses and dashed
line; non-carriers: circles and solid line.
.................................................................. ..................................................................
.............................................................................................................................................................................................
Table I Sample characteristics.
BRCA1 BRCA2
Carriers Non-Carriers P-value Carriers Non-Carriers P-value
n 5 172 n 5 216 n 5 147 n 5 158
Year of birth* 1968 (7.2) 1966 (6.9) 0.003 1969 (7.0) 1967 (7.0) 0.01
Age at blood draw (years)* 34.2 (5.7) 35.8 (5.8) 0.006 34.4 (5.6) 35.8 (5.6) 0.03
Years sample was stored* 11.4 (3.9) 11.9 (3.3) 0.15 10.8 (3.7) 11.4 (3.6) 0.17
Cigarette use**, n (%)
Never 84 (49) 97 (45) 75 (51) 76 (48)
Past 39 (23) 64 (30) 45 (31) 46 (29)
Current 49 (28) 55 (25) 0.31 27 (18) 36 (23) 0.65
Body mass index* (kg/m2) 24.8 (5.2) 26.2 (6.4) 0.02 25.4 (6.0) 25.4 (5.3) 0.99
OCP use at blood draw, n (%)
No 150 (87) 183 (85) 118 (80) 139 (88)
Yes 22 (13) 33 (15) 0.56 29 (20) 19 (12) 0.08
Infertility treatment, n (%)
Ever 10 (6) 10 (5) 8 (5) 11 (7)
Never 161 (94) 205 (95) 0.65 135 (92) 142 (90) 0.64
Don’t know 1 (1) 1 (0.5) 4 (3) 5 (3)
Parity, n (%)
Nulliparous 46 (27) 65 (30) 53 (36) 48 (30)
Parous 126 (73) 151 (70) 0.50 94 (64) 110 (69) 0.33
Age at ﬁrst birth* (years) 24.9 (4.7) 25.0 (5.1) 0.76 25.7 (4.4) 25.6 (4.7) 0.87
All values ,0.05 are statistically signiﬁcant.
n, number; OCP, oral contraceptive pill.
*Mean (standard deviation).
**Regular cigarette smoking—at least one per day for 3 months or longer.
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Our ﬁndings are consistent with pioneering observations in 2010 that
breast cancer patients with germline BRCA1 mutations undergoing
ovarian stimulation for fertility preservation prior to chemotherapy
had lower oocyte yields compared with women not known to be
BRCA1 mutation carriers or who carried a BRCA2 mutation (Oktay
et al., 2010). Low oocyte yields from ovarian stimulation predict lower
likelihood of pregnancy and earlier age at menopause (de Boer et al.,
2002). Some studies have suggested that women with BRCA1mutations
experience earlier menopause than non-carriers (Rzepka-Gorska et al.,
2006; Finch et al., 2013; Lin et al., 2013). In a previous study of the
kConFab cohort,wedid not ﬁnd adifference in age at naturalmenopause
between BRCA1 or BRCA2 mutation carriers and their non-carrier rela-
tives (Collins et al., 2013). However, that observation could have been
confounded; for example, mutation carriers who seemed destined for
an earlier menopause (e.g. because their menses were becoming irregu-
lar) may have been more likely to choose cancer risk-reducing bilateral
salpingo-oophorectomy at an early age (and therefore be censored
from the analysis), biasing the study ﬁndings toward the null. Another
limitation of our previous study was that only 19% of the cohort had
undergone natural menopause.
Our newﬁndings are consistent with some smaller studies.Wang et al
found lower AMH concentrations in a group of 62 BRCA1mutation car-
riers comparedwith54unrelatednon-carriers, but nodifference inAMH
levels between 27 BRCA2 mutation carriers and non-carriers (Wang
et al., 2014). Titus et al found similar results in a study of 15 BRCA1mu-
tation carriers, 9 BRCA2 mutation carriers and 60 non-carriers (Titus
et al., 2013). Pavone et al found that AMH concentrations were similar
between 66 BRCA1 mutation carriers and 59 non-carriers, but lower
for BRCA1 mutation carriers aged 35–39 years (Pavone et al., 2014).
Another study found no difference in the AMH concentrations
between 41 BRCA1 and BRCA2mutation carriers (pooled) and 324 con-
trols (Michaelson-Cohen et al., 2014). Our study overcomes several
methodologic limitations of these previous reports; speciﬁcally we had
a larger sample size, detailed information about potential confounders
such as age, OCP use, BMI, and cigarette smoking, and we used non-
carriers (controls) from the same families as mutation carriers (cases)
which, by design, adjusts in part for unmeasured genetic factors that
might inﬂuence ovarian reserve.
High-ﬁdelity double-strandDNAbreak repair is critical tomitosis and
meiosis (Bolcun-Filas et al., 2014), and other genetic diseases character-
ized by deﬁcient homologous recombination andDNArepair are known
to be associated with subfertility due to accelerated oocyte apoptosis
(Titus et al., 2013). A recent large scale genomic analysis by Day et al
(Day et al., 2015) extended the ﬁndings of a prior genome-wide associ-
ation study (Stolk et al., 2012) and showed that genetic variants in several
DNA repair enzymes, including BRCA1, are associated with age at
menopause in large populations, providing further evidence for the im-
portance of DNA repair processes in determining reproductive lifespan.
Oocyte meiosis is characterized by very prolonged arrest at meiosis I,
from fetal life until ovulation which might be decades later. This pro-
longed arrest highlights the importance of maintaining chromosome/
genetic integrity, which underpins oocyte health and survival over a
very protracted period. Thus our ﬁnding of reduced AMH concentra-
tions for carriers ofmutations in BRCA1, a gene that is critically important
in the repair of double-strand DNA breaks, has biologic plausibility.
BRCA2has amore limited role in double-strandDNAbreak repair com-
pared with BRCA1 and BRCA2mutation carriers tend to develop fewer
Figure2 AMH levels in BRCA2mutation carrier families, bymutation
carrier status. Solid and dashed lines are drawn by locally weighted re-
gression of log-transformed AMH levels. Carriers: crosses and dashed
line; non-carriers: circles and solid line.
.............................................................................................................................................................................................
Table II Estimated coefﬁcient (b) for mutation carriers versus non-carriers from linear regression modelling the natural
logarithm of AMH as the outcome variable.
Model BRCA1
b (95% CI), P-value
BRCA2
b (95% CI), P-value
All women, adjusted for:
– age* only 20.29 (20.53, 20.05), 0.02 20.05 (20.31, 0.21), 0.71
– age*, OCP use, BMI, smoking 20.28 (20.54, 20.03), 0.03 20.01 (20.26, 0.24), 0.94
– age*, OCP use, BMI, smoking, time to blood draw 20.28 (20.53, 20.03), 0.03 0.00 (20.25, 0.25), 0.99
Excluding current OCP users & post-menopausal and unknown menopausal status at
time of blood draw#
20.30 (20.55, 20.06), 0.02 20.03 (20.31, 0.26), 0.85
CI, conﬁdence interval.
*Adjustment for age included a linear and quadratic term.
#Adjusted for age, OCP use, BMI, smoking.
BRCA1 or BRCA2 mutations and serum AMH levels 5
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cancers and at a later age, compared with BRCA1 mutation carriers
(Antoniou et al., 2003). Thus it is credible that any effect of mutation
statusonovarian reservewouldbemorepronounced inBRCA1mutation
carriers and this observation has been made in mouse models (Titus
et al., 2013).
BRCA1 mutation carriers are at increased risk of ovarian and fallopian
tube cancers and so are advised to consider bilateral salpingo-oophorec-
tomyafter completion of childbearing and preferablywhile premenopausal
(National Comprehensive Cancer Network, 2008) because such timing
also reduces breast cancer risk (Domchek et al., 2010). Some BRCA1mu-
tation carriersmay therefore choose early childbearing in order to facilitate
early bilateral salpingo-oophorectomy.Our study found that BRCA1muta-
tion carriers had, on average, 25% (95% CI: 5–41%, P ¼ 0.02) lower
AMH concentrations than non-carriers and were more likely to have
AMH concentrations in the lowest quartile for age (OR 1.84, 95% CI:
1.11–303, P ¼ 0.02). There was no evidence of an association between
AMH concentration and BRCA2 mutation status (P ¼ 0.94). Further
research is required to fully understand the direct clinical implications
of these ﬁndings, in terms of fertility, nevertheless they suggest that
BRCA1 mutation carriers should try to avoid delaying pregnancy until
later reproductive ages. Our ﬁndings also raise the hypothesis that
BRCA1 mutation carriers may have a higher than average risk of
chemotherapy-induced menopause (Anderson and Cameron, 2011);
but this requires further study. Importantly our ﬁndings may shed new
light onmechanisms of age-related fertility decline, themost common indi-
cation for assisted reproduction treatment.
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